478 related articles for article (PubMed ID: 30280836)
21. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice.
Lebre F; Borchard G; Faneca H; Pedroso de Lima MC; Borges O
Mol Pharm; 2016 Feb; 13(2):472-82. PubMed ID: 26651533
[TBL] [Abstract][Full Text] [Related]
22. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
23. Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.
Saeed MI; Omar AR; Hussein MZ; Elkhidir IM; Sekawi Z
Hum Vaccin Immunother; 2015; 11(10):2414-24. PubMed ID: 26186664
[TBL] [Abstract][Full Text] [Related]
24. Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.
Yue Y; Xu W; Xiong S
DNA Cell Biol; 2012 Apr; 31(4):479-88. PubMed ID: 21988406
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori.
Xing Y; Liu W; Li X; Guo L; Lv X; Xi T
Biochem Biophys Res Commun; 2015 Jul; 462(3):269-74. PubMed ID: 25957472
[TBL] [Abstract][Full Text] [Related]
26. Chitosan-based delivery systems for mucosal vaccines.
Jabbal-Gill I; Watts P; Smith A
Expert Opin Drug Deliv; 2012 Sep; 9(9):1051-67. PubMed ID: 22708875
[TBL] [Abstract][Full Text] [Related]
27. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
[TBL] [Abstract][Full Text] [Related]
29. A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity.
Khademi F; Derakhshan M; Yousefi-Avarvand A; Najafi A; Tafaghodi M
Microb Pathog; 2018 Dec; 125():507-513. PubMed ID: 30352265
[TBL] [Abstract][Full Text] [Related]
30. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
Slütter B; Jiskoot W
J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
[TBL] [Abstract][Full Text] [Related]
31. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.
Smith A; Perelman M; Hinchcliffe M
Hum Vaccin Immunother; 2014; 10(3):797-807. PubMed ID: 24346613
[TBL] [Abstract][Full Text] [Related]
32. Chitosan-based mucosal adjuvants: Sunrise on the ocean.
Xia Y; Fan Q; Hao D; Wu J; Ma G; Su Z
Vaccine; 2015 Nov; 33(44):5997-6010. PubMed ID: 26271831
[TBL] [Abstract][Full Text] [Related]
33. Mucosal immunisation: adjuvants and delivery systems.
Moyle PM; McGeary RP; Blanchfield JT; Toth I
Curr Drug Deliv; 2004 Oct; 1(4):385-96. PubMed ID: 16305400
[TBL] [Abstract][Full Text] [Related]
34. Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.
Zuo Z; Zou Y; Li Q; Guo Y; Zhang T; Wu J; He C; Eko FO
Sci Rep; 2021 May; 11(1):10389. PubMed ID: 34001988
[TBL] [Abstract][Full Text] [Related]
35. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
[TBL] [Abstract][Full Text] [Related]
36. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
37. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity.
Noh YW; Hong JH; Shim SM; Park HS; Bae HH; Ryu EK; Hwang JH; Lee CH; Cho SH; Sung MH; Poo H; Lim YT
Angew Chem Int Ed Engl; 2013 Jul; 52(30):7684-9. PubMed ID: 23765547
[TBL] [Abstract][Full Text] [Related]
38. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
Front Immunol; 2018; 9():783. PubMed ID: 29720976
[TBL] [Abstract][Full Text] [Related]
39. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
40. Nasal and pulmonary vaccine delivery using particulate carriers.
Jia Y; Krishnan L; Omri A
Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
